School of Medicine
  • Print
Medical tablets, capsules and caplets flying out of a bottle against a light blue background

People

Lindy Durrant

Professor of Cancer Immunotherapy, Faculty of Medicine & Health Sciences

Contact

Biography

Lindy Durrant BSc, PhD

Professor of Cancer Immunotherapy,

University of Nottingham

Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed a panel of mabs recognised tumour associated glycans and has pioneered an new antibody engineering technology which enhances the avidity of mabs, termed Avidimabs. This has been applied to the anti-glycan mabs resulting in direct killing mabs. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer reviewed publications and is also the inventor on 66 patents. She was award of the Waldenstrom prize for cancer Immunotherapy in 2019.

The cancer vaccine group have developed a unique DNA vaccine platform to stimulate high avidity T cells which efficiently kill tumour cells. The lead vaccine for the treatment of Melanoma is due to enter the clinic in June 2010

Expertise Summary

Immunotherapy, Monoclonal antibodies and T cell biology

Teaching Summary

Lecture on Cancer immunotherapy and sett up a business

Research Summary

Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed a panel of mabs recognised tumour associated glycans and has pioneered an new… read more

Selected Publications

Current Research

Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed a panel of mabs recognised tumour associated glycans and has pioneered an new antibody engineering technology which enhances the avidity of mabs, termed Avidimabs. This has been applied to the anti-glycan mabs resulting in direct killing mabs. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer reviewed publications and is also the inventor on 66 patents. She was award of the Waldenstrom prize for cancer Immunotherapy in 2019.

Future Research

We have identified a common process that occurs in most cancer that can be recognised by the immune system. This would allow us to design a vaccine to stimulate an immune response which would recognise and kill early cancerous cells. This may have to be boosted yearly as for seasonal flu vaccines. It could be given to people at high risk of cancer or to adults over 60 which are the most common age group for this disease.

School of Medicine

University of Nottingham
Medical School
Nottingham, NG7 2UH

Contacts: Please see our 'contact us' page for further details